Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UCART123v1.2 in Relapsed/Refractory AML
NCT03190278Phase 1Active, not recruiting
- Sponsor
- Cellectis
- Start
- Jun 2017
- Primary completion
- Dec 2024
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of UCART123 in acute myeloid leukemia (AML), sponsored by Cellectis. Primary endpoints: Incidence of adverse events (AE)/serious adverse events (SAE)/Dose Limiting Toxicities (DLT) at 24 months and Occurrence of Dose Limiting Toxicities (DLTs). Started Jun 2017; status: active, not recruiting.
02
Drugs
UCART123
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03190278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03190278.